Cyrano Therapeutics Reports Positive Phase II Data for CYR-064 in Post-Viral Hyposmia

Cyrano Therapeutics has announced positive topline results from its Phase II FLAVOR trial evaluating CYR-064, an intranasal soft-mist spray for persistent post-viral hyposmia. The randomised, double-blind, placebo-controlled study enrolled 151 patients across 14 US sites with smell loss lasting at least six months.

The trial met its primary endpoint, demonstrating that CYR-064 was safe and well tolerated, with no treatment-related serious adverse events. Durable improvements in olfactory function were observed across multiple prespecified secondary endpoints.

Hyposmia, a chronic sensory disorder following viral infection, significantly affects smell and taste, reducing quality of life and increasing health risks. CYR-064 combines a broad-spectrum phosphodiesterase inhibitor with targeted intranasal delivery to stimulate olfactory neurons.

Cyrano plans to present full data in 2026, positioning CYR-064 as a potential first approved therapy for persistent post-viral smell loss.

28-02-2026